GlassScriptPhysician profile
Mikhaile Ramos
NPI 1639500085
$1,527.50
in general payments reported to CMS, 2019-2025
19 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $35.85 · 2023: $519 · 2024: $515 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $307.37 | 2023-2025 | Epclusa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $194.68 | 2023-2025 | Caplyta |
| Abbvie INC. | $139.75 | 2022-2024 | |
| Exact Sciences Corporation | $129.22 | 2023-2025 | Cologuard Collection Kit |
| Insulet Corporation | $89.48 | 2025 | Omnipod |
| Pfizer INC. | $85.62 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $85.30 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Mylan Specialty L.P. | $69.62 | 2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $68.05 | 2025 | Uzedy |
| Lilly USA, LLC | $66.39 | 2024-2025 | Mounjaro, Zepbound |
| Neurocrine Biosciences, INC. | $66.00 | 2023-2025 | Ingrezza |
| Novo Nordisk INC | $48.58 | 2023-2024 | Wegovy |
| Janssen Pharmaceuticals, INC | $48.47 | 2023-2024 | Spravato |
| Dexcom, INC. | $38.79 | 2023-2025 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $21.30 | 2025 | Yupelri |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $20.30 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $19.78 | 2023 | |
| Astellas Pharma US INC | $19.40 | 2025 | Veozah |
| Organon LLC | $9.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhaile Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.